TITLE

Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress

AUTHOR(S)
Hayden, Melvin R.; Tyagi, Suresh C.
PUB. DATE
January 2003
SOURCE
Cardiovascular Diabetology;2003, Vol. 2, p2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Cardiovascular disease accounts for at least 85 percent of deaths for those patients with type 2 diabetes mellitus (T2DM). Additionally, 75 percent of these deaths are due to ischemic heart disease. Hypothesis: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Testing of the hypothesis: The vulnerable three arms of the eNOS reaction responsible for the generation of eNO is discussed in relation to the hypothesis: (1). The L-arginine substrate. (2). The eNOS enzyme. (3). The BH4 cofactor. Implications of the hypothesis: If we view T2DM as a vascular disease initially with a later manifestation of hyperglycemia, we may be able to better understand and modify the multiple toxicities associated with insulin resistance, metabolic syndrome, prediabetes, overt T2DM, and accelerated atherosclerosis (atheroscleropathy). The importance of endothelial nitric oxide synthase, endothelial nitric oxide, tetrahydrobiopterin (BH4), L-arginine, and redox stress are discussed in relation to endothelial cell dysfunction and the development and progression of atheroscleropathy and T2DM. In addition to the standard therapies to restore endothelial cell dysfunction and stabilization of vulnerable atherosclerotic plaques, this article will discuss the importance of folic acid (5MTHF) supplementation in this complex devastating disease process. Atheroscleropathy and hyperglycemia could be early and late manifestations, respectively, in the natural progressive history of T2DM.
ACCESSION #
28683667

 

Related Articles

  • UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Adler, Amanda I.; Stevens, Richard J.; Stratton, Irene M.; Holman, Rury R.; Neil, Andrew; Boulton, Andrew J. M. // Diabetes Care;May2002, Vol. 25 Issue 5, p894 

    Objective: To determine the role of hyperglycemia in prospective analyses of peripheral vascular disease (PVD) in type 2 diabetes, taking into account other potential risk factors. Research Design and Methods: Potential risk factors for the development of PVD were...

  • Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance. Markolf Hanefeld; Frank Schaper; Carsta Koehler // Cardiovascular Drugs & Therapy;Jun2008, Vol. 22 Issue 3, p225 

    Abstract Introduction  Excessive postprandial (pp) glucose excursion in people with IGT and type 2 diabetes is associated with a cascade of proatherogenic events. Acarbose, a potent competitive inhibitor of α-glucosidases of the small intestine specifically reduces pp hyperglycemia with...

  • The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Wiernsperger, N.F.; Bailey, C.J. // Drugs;Dec1999 Supplement 1, Vol. 58 Issue 6, p31 

    Metformin is regarded as an antihyperglycaemic agent because it lowers blood glucose concentrations in type 2 (non-insulin-dependent) diabetes without causing overt hypoglycaemia. Its clinical efficacy requires the presence of insulin and involves several therapeutic effects. Of these effects,...

  • A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus. Howlett, H.C.S.; Bailey, C.J. // Drug Safety;Jun1999, Vol. 20 Issue 6, p489 

    Metformin has been used for over 40 years as an effective glucose-lowering agent in type 2 (noninsulin-dependent) diabetes mellitus. Typically it reduces basal and postprandial hyperglycaemia by about 25% in more than 90% of patients when either given alone or coadministered with other therapies...

  • Hemodynamic Effects of Acute Hyperglycemia in Type 2 Diabetic Patients. Marfella, Raffaele; Nappo, Francesco; De Angelis, Lorenita; Paolisso, Giuseppe; Tagliamonte, Maria Rosaria; Giugliano, Dario // Diabetes Care;May2000, Vol. 23 Issue 5, p658 

    Focuses on a study which evaluated the hemodynamic effects of acute hyperglycemia in type 2 diabetic patients and to see whether these effects are related to changes in nitric oxide availability. Research design and methods; Results; Conclusions.

  • The Efficacy of Acarbose in the Treatment of Patients with non-Insulin-dependent Diabetes Mellitus. Chiasson, Jean Louis; Josse, Robert G.; Hunt, John A.; Palmason, Carol; Rodger, N. Wilson; Ross, Stuart A.; Ryan, Edmond A.; Tan, Meng H.; Wolever., Thomas M.S. // Annals of Internal Medicine;12/15/94, Vol. 121 Issue 12, p928 

    Presents a study which evaluated the long-term efficacy of acarbose, an alpha-glucosidase inhibitor, in improving glycemic control in patients with non-insulin-dependent diabetes mellitus. Alternative approach to the problem of postprandial hyperglycemia; Methods used in the study; Results and...

  • Morning Hyperglycemic Excursions. Monnier, Louis; Rabasa-Lhoret, Remy; Lapinski, Helene; Caubel, Cecile; Avignon, Antoine; Boniface, Helene; Colette, Claude // Diabetes Care;Apr2002, Vol. 25 Issue 4, p737 

    Presents a study that determined whether, over daytime, one or several hyperglycemic excursions exist that can be general failures in the glycemic control of patients with type 2 diabetes. Protocol of the study and analytical procedures; Comparison of plasma glucose and insulin concentrations...

  • Type 2 Diabetes Impairs Splanchnic Uptake of Glucose but Does Not Alter Intestinal Glucose Absorption During Enteral Glucose Feeding. Basu, Ananda; Basu, Rita; Shah, Pankaj; Vella, Adrian; Johnson, C. Michael; Jensen, Michael; Nair, K. Sreekumaran; Schwenk, W. Frederick; Rizza, Robert A. // Diabetes;Jun2001, Vol. 50 Issue 6, p1351 

    Focuses on the effects of diabetes on the splanchnic uptake of glucose. Decrease in the contribution of extracellular pathway to hepatic glycogen synthesis; Role of abnormal hepatic and muscle glucose metabolism on postprandial hyperglycemia; Characterization of type 2 diabetes.

  • Managing hyperglycemia in Type 2 diabetes: Here's how. Fernandez, Julio // Drug Topics;9/18/2006, Vol. 150 Issue 18, p25 

    The article presents an instructional material on the management of hyperglycemia in patients with non-insulin-dependent diabetes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics